NCT03492437View on ClinicalTrials.gov

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 17, 2018

Primary Completion Date

August 27, 2018

Study Completion Date

August 27, 2018

Conditions
Healthy
Interventions
DRUG

Dabigatran Etexilate

Participants received single oral dose of Dabigatran etexilate on Day 1 of Treatment period 1 and co-administration of Dabigatran with Tepotinib on Day 8 of Treatment period 2.

DRUG

Tepotinib

Participants received single oral dose of Tepotinib for 8 days in Treatment period 2.

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03492437 - Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate | Biotech Hunter | Biotech Hunter